Kathryn Romano Sells 750 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Krystal Biotech Stock Up 3.4 %

Shares of Krystal Biotech stock opened at $179.25 on Friday. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34. The company’s 50-day simple moving average is $159.41 and its 200-day simple moving average is $175.17. The firm has a market cap of $5.16 billion, a price-to-earnings ratio of 59.95 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same period in the previous year, the business posted $0.30 earnings per share. The business’s revenue was up 116.4% compared to the same quarter last year. Equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on KRYS shares. Chardan Capital raised their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. HC Wainwright reissued a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Friday. Citigroup raised their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $215.83.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in KRYS. Wilmington Savings Fund Society FSB purchased a new stake in Krystal Biotech during the third quarter worth about $40,000. GF Fund Management CO. LTD. purchased a new stake in Krystal Biotech during the fourth quarter worth about $95,000. Huntington National Bank boosted its holdings in Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after buying an additional 283 shares in the last quarter. Covestor Ltd boosted its holdings in Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after buying an additional 642 shares in the last quarter. Finally, KBC Group NV boosted its holdings in Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after buying an additional 132 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).